AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

At an event held in the House of Lords on 5th November, The Trade Facilitation Commission released their detailed report and ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Kamala Harris lost 2024 US election, 10 large-cap stocks performed poorly: Moderna, Honda, Akamai, ADS, AstraZeneca, ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal ...